These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16303033)

  • 41. Lansoprazole-induced subacute cutaneous lupus erythematosus: two cases.
    Bracke A; Nijsten T; Vandermaesen J; Meuleman L; Lambert J
    Acta Derm Venereol; 2005; 85(4):353-4. PubMed ID: 16191862
    [No Abstract]   [Full Text] [Related]  

  • 42. Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube.
    Messaouik D; Sautou-Miranda V; Bagel-Boithias S; Chopineau J
    Int J Pharm; 2005 Aug; 299(1-2):65-72. PubMed ID: 15990258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Drug preparations of proton pump inhibitors].
    Breitkreutz J
    Pharm Unserer Zeit; 2005; 34(3):216-23. PubMed ID: 15940955
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of Elevated pH on the Commercial Enteric-Coated Omeprazole Pellets Resistance: Patent Review and Multisource Generics Comparison.
    Mohylyuk V; Yerkhova A; Katynska M; Sirko V; Patel K
    AAPS PharmSciTech; 2021 Jun; 22(5):188. PubMed ID: 34159427
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum cholinesterase inhibition by omeprazole and lansoprazole.
    Mequid S; Ramzan I
    Pharmazie; 2004 Sep; 59(9):733. PubMed ID: 15497763
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proton-pump inhibitors for upper-gastrointestinal bleeding.
    Cohen H; Rebuck JA
    Am J Health Syst Pharm; 2006 Feb; 63(3):214, 216. PubMed ID: 16434778
    [No Abstract]   [Full Text] [Related]  

  • 47. Proton-pump inhibitors for upper-gastrointestinal bleeding.
    Rivkin K; Lyakhovetskiy A
    Am J Health Syst Pharm; 2006 Feb; 63(3):216-7. PubMed ID: 16434779
    [No Abstract]   [Full Text] [Related]  

  • 48. Proton-pump inhibitor for peptic ulcer bleeding.
    Zullo A; Hassan C; Morini S
    Aliment Pharmacol Ther; 2005 Nov; 22(9):891-2; author reply 892. PubMed ID: 16225502
    [No Abstract]   [Full Text] [Related]  

  • 49. Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration.
    Hussain FN; Ajjan RA; Moustafa M; Weir NW; Riley SA
    Br J Clin Pharmacol; 1998 Aug; 46(2):173-5. PubMed ID: 9723828
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nephritis and proton pump inhibitors.
    Prescrire Int; 2004 Feb; 13(69):21. PubMed ID: 15055222
    [No Abstract]   [Full Text] [Related]  

  • 51. [Pharmacology of proton pump inhibitors].
    Klotz U
    Pharm Unserer Zeit; 2005; 34(3):200-4. PubMed ID: 15940952
    [No Abstract]   [Full Text] [Related]  

  • 52. Omeprazole may delay gastric emptying?
    DeVault KR
    Am J Gastroenterol; 1996 Sep; 91(9):1869-70. PubMed ID: 8792725
    [No Abstract]   [Full Text] [Related]  

  • 53. Proton pump inhibitors--differences emerge in hepatic metabolism.
    McColl KE; Kennerley P
    Dig Liver Dis; 2002 Jul; 34(7):461-7. PubMed ID: 12236477
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantification of omeprazole degradation by enteric coating polymers: an UV-VIS spectroscopy study.
    Riedel A; Leopold CS
    Pharmazie; 2005 Feb; 60(2):126-30. PubMed ID: 15739901
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effect of proton pump inhibitors. In vivo is decisive].
    MMW Fortschr Med; 2002 Mar; 144(13):51. PubMed ID: 12001593
    [No Abstract]   [Full Text] [Related]  

  • 56. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms.
    Hoffman A; Stepensky D; Lavy E; Eyal S; Klausner E; Friedman M
    Int J Pharm; 2004 Jun; 277(1-2):141-53. PubMed ID: 15158977
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Focus on proton pump inhibitors. The phenomenon of (over)compensation is not odd but normal].
    Melander A
    Lakartidningen; 2003 Mar; 100(11):923. PubMed ID: 15148718
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacokinetics of intravenous omeprazole in critically ill paediatric patients.
    Solana MJ; López-Herce J
    Eur J Clin Pharmacol; 2010 Apr; 66(4):323-30. PubMed ID: 20041322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proton pump inhibitors reduce gallbladder function.
    Cahan MA; Balduf L; Colton K; Palacioz B; McCartney W; Farrell TM
    Surg Endosc; 2006 Sep; 20(9):1364-7. PubMed ID: 16858534
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factors Contributing to Drug Release From Enteric-Coated Omeprazole Capsules: An In Vitro and In Vivo Pharmacokinetic Study and IVIVC Evaluation in Beagle Dogs.
    Cui C; Sun J; Wang X; Yu Z; Shi Y
    Dose Response; 2020; 18(1):1559325820908980. PubMed ID: 32180688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.